Search research articles
Contact Us
Filters
Showing results (411-420 of 564) with videos related to
Page
of 57
Sort By:
European Urology
|
August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings
Cora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles, Se Hoon Park, Claudia Caserta, et al.
Future Oncology (London, England)
|
September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Petros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Cancers
|
February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
Pauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Nature Medicine
|
December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles, Srikala S Sridhar, Yohann Loriot, et al.
Page
of 57
Search research articles
Search
Showing results (411-420 of 564) with videos related to
Sort By:
Page
of 57
European Urology
|
August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings
Cora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles, Se Hoon Park, Claudia Caserta, et al.
Future Oncology (London, England)
|
September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Petros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Cancers
|
February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
Pauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Nature Medicine
|
December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles, Srikala S Sridhar, Yohann Loriot, et al.
Page
of 57